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background
 
The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is
controversial and is not a recommended intervention.
 
methods
 
We randomly assigned 760 consecutive adult patients with cancer in whom chemother-
apy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to
occur for more than seven days to receive either oral levofloxacin (500 mg daily) or pla-
cebo from the start of chemotherapy until the resolution of neutropenia. Patients were
stratified according to their underlying disease (acute leukemia vs. solid tumor or lym-
phoma).
 
results
 
An intention-to-treat analysis showed that fever was present for the duration of neutro-
penia in 65 percent of patients who received levofloxacin prophylaxis, as compared with
85 percent of those receiving placebo (243 of 375 vs. 308 of 363; relative risk, 0.76; ab-
solute difference in risk, ¡20 percent; 95 percent confidence interval, ¡26 to ¡14 percent;
P=0.001). The levofloxacin group had a lower rate of microbiologically documented
infections (absolute difference in risk, ¡17 percent; 95 percent confidence interval,
¡24 to ¡10 percent; P<0.001), bacteremias (difference in risk, ¡16 percent; 95 percent
confidence interval, ¡22 to ¡9 percent; P<0.001), and single-agent gram-negative bac-
teremias (difference in risk, ¡7 percent; 95 percent confidence interval, ¡10 to ¡2 per-
cent; P<0.01) than did the placebo group. Mortality and tolerability were similar in the
two groups. The effects of prophylaxis were also similar between patients with acute
leukemia and those with solid tumors or lymphoma.
 
conclusions
 
Prophylactic treatment with levofloxacin is an effective and well-tolerated way of pre-
venting febrile episodes and other relevant infection-related outcomes in patients with
cancer and profound and protracted neutropenia. The long-term effect of this inter-
vention on microbial resistance in the community is not known.
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acterial infections are a major
 
cause of complications and death in pa-
tients with hematologic cancers and che-
motherapy-induced neutropenia. A number of ran-
domized clinical trials and two meta-analyses
 
1,2
 
have suggested that prophylaxis with fluoroquino-
lones may be better than placebo or trimethoprim–
sulfamethoxazole in reducing bacteremic infections
caused by gram-negative bacilli, with ciprofloxacin
being the compound most widely used.
 
3
 
 However,
the evidence provided by these studies is not seen
as entirely convincing. 
First, only three studies were placebo-controlled,
double-blind, randomized clinical trials, and none
were sufficiently large to provide conclusive evi-
dence of the real efficacy of prophylaxis.
 
4-6
 
 Second,
in most studies, the occurrence of fever requiring
empirical antibiotic therapy was not considered or
was not significantly reduced by prophylaxis.
 
1
 
Third, these studies did not address the important
question of whether prophylaxis should be consid-
ered for all patients with cancer and neutropenia,
since the risk of infection may differ among such
patients. Fourth, in all studies, prophylaxis with flu-
oroquinolones did not reduce the risk of infections
caused by gram-positive microorganisms. Finally,
the routine use of fluoroquinolone prophylaxis in
patients with cancer and neutropenia has been ques-
tioned, because it can increase bacterial resistance
to these agents
 
7-9
 
 and thus limit their efficacy in re-
ducing infection-related morbidity or mortality. 
To clarify these issues, we conducted a large,
double-blind, placebo-controlled clinical trial using
levofloxacin, a fluoroquinolone with an extended
spectrum against gram-positive bacteria, as a pro-
phylactic agent in adult patients with cancer in
whom profound and prolonged chemotherapy-
induced neutropenia was expected to develop.
 
patients
 
Consecutive adult patients with acute leukemia,
solid tumors, or lymphoma who were hospitalized
at participating centers and who were at risk for
chemotherapy-induced neutropenia (absolute neu-
trophil count less than 1000 per cubic millimeter)
lasting more than seven days were eligible for the
study. Patients were enrolled only once in the study.
Patients undergoing allogeneic stem-cell transplan-
tation, patients with a history of hypersensitivity to
fluoroquinolones, those treated with antimicrobial
therapy in the preceding five days, and those with
fever of infectious origin or a documented infection
at the time of enrollment were excluded.
All patients entered the study one to three days
before the administration of cytotoxic chemother-
apy. Among recipients of hematopoietic stem-cell
transplants, prophylaxis was started within three
days before or after the reinfusion of stem cells.
 
study design
 
The study was designed as a prospective, multi-
center, double-blind, randomized, placebo-con-
trolled trial and was approved by the ethics com-
mittee at each participating center. The study was
conducted between April 30, 2001, and March 18,
2003, at 35 centers in Italy by a committee that in-
cluded all the authors. At entry, after having provid-
ed written informed consent, patients were assigned
to receive 500 mg of levofloxacin orally, once daily,
or an identical-appearing placebo, according to a
computer-generated random-number program ac-
cessible 24 hours a day. Patients were stratified ac-
cording to the center and the underlying disease
(solid tumors or lymphoma vs. acute leukemia). Pa-
tients with acute leukemia were presumed to have
longer and more profound neutropenia (fewer than
100 neutrophils per cubic millimeter) and thus were
in the high-risk stratum, whereas patients with solid
tumors and lymphoma who were undergoing hema-
topoietic stem-cell transplantation were in the
stratum at low risk for infection. Prophylaxis was
continued in all patients until neutropenia had re-
solved.
Randomized patients were examined daily for
clinical signs of infection. When axillary tempera-
ture exceeded 38.5°C once or 38°C at least twice
during a period of 12 hours and an infection was
suspected, samples were obtained for microbiolog-
ic cultures, including at least two separate blood
specimens, and empirical antibacterial therapy was
initiated, according to the judgment of the investi-
gator. Isolated bacteria were identified with the use
of standard methods, and susceptibility was evalu-
ated at each center according to the Kirby–Bauer
method.
 
10
 
 Infections were classified according to
the definitions of the European Organization for
Research and Treatment of Cancer.
 
11
 
 Compliance
was monitored by counting pills. The primary end
point of the study was the occurrence of fever re-
quiring empirical antibacterial therapy during neu-
b
methods
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tropenia. Secondary end points were the type and
number of documented infections, the use of par-
enteral antimicrobial agents during neutropenia,
survival at the resolution of neutropenia, compli-
ance, and tolerability. The costs of antimicrobial
agents used during neutropenia excluding prophy-
laxis were calculated according to the Italian Na-
tional Drug Formulary.
 
12
 
statistical analysis
 
We assumed that fever of infectious origin occurs
in approximately 80 percent of patients with che-
motherapy-induced neutropenia who are not re-
ceiving antibacterial prophylaxis.
 
13,14
 
 We estimat-
ed that at least 300 patients (150 in each group)
would be needed in each stratum to detect an abso-
lute difference of at least 15 percent between levo-
floxacin and placebo with a statistical power of 80
percent and a 5 percent significance level. Because
we also assumed that 20 percent of patients would
not be included in the efficacy analysis, we set an
enrollment goal of at least 750 patients (375 in
each group).
All case-report forms were centrally reviewed
and statistical analysis was carried out at the Grup-
po Italiano Malattie Ematologiche dell’Adulto
(GIMEMA) Infection Program Data Center with the
use of the SAS software package (SAS Institute). All
evaluations were made in a blinded fashion with
respect to the assigned treatment. An analysis that
included all eligible patients was conducted accord-
ing to the intention to treat by considering that treat-
ment was successful in all patients without fever
during the study whose response could not be as-
sessed because they were lost to follow-up. A per-
protocol analysis was conducted that included all
assessable patients, and a subanalysis of this group
that included only patients with neutropenia last-
ing at least seven days was also performed. Efficacy
with respect to the primary and secondary end
points was expressed as the absolute difference in
rates between treatment groups (the rate with levo-
floxacin minus the rate with placebo). The 95 per-
cent confidence interval for the difference between
proportions is given, as is the relative risk of the
primary end point. The chi-square test with a cor-
rection for continuity was used to compare propor-
tions. The Wilcoxon rank-sum test was used to com-
pare the means, and a logistic-regression model was
used to assess the relative importance of the various
prognostic factors assessable at the time of random-
ization (the types of prophylaxis, the duration of
neutropenia, the underlying disease, and the pres-
ence or absence of protective isolation and a central
venous catheter). Kaplan–Meier estimates of sur-
vival without fever were also determined. Differenc-
es in survival without fever were assessed with a log-
rank test at the 5 percent significance level.
The study was designed and the article was writ-
ten by Drs. Del Favero, Bucaneve, Menichetti, Mar-
tino, and Micozzi, coordinators of the GIMEMA
Infection Program. The data were collected, held,
and analyzed by the coordinators with the help of
the data-review committee (see the Appendix) at the
GIMEMA data center. All the authors helped write
the article and reviewed the manuscript. The two
companies that helped support the study did not
have any involvement in the conduct of the trial and
had no role with respect to the project design, con-
duct of the study, data analysis, or writing of the
manuscript, all of which were carried out exclu-
sively by the investigators at the GIMEMA data cen-
ter at Perugia University (Italy). During the study
period, the only communication between the spon-
sors and investigators was related to the monitor-
ing of enrollment and the reporting of adverse
events. 
A total of 760 patients with neutropenia were en-
rolled: 384 were randomly assigned to receive oral
levofloxacin, and 376 to receive placebo. The out-
comes are shown in Figure 1. The characteristics of
the 675 patients whose response to therapy could
be assessed are provided in Table 1. There were no
significant differences between the two groups
within each stratum of disease.
 
febrile episodes
 
An intention-to-treat analysis showed that fever
developed in 65 percent of patients in the levoflox-
acin group, as compared with 85 percent of those
in the placebo group (243 of 375 vs. 308 of 363; rel-
ative risk, 0.76; absolute difference in risk, ¡20 per-
cent; 95 percent confidence interval, ¡26 to ¡14 per-
cent; P=0.001). A per-protocol analysis of patients
whose response to treatment could be assessed as
well as a subanalysis of this group including only the
patients with neutropenia lasting at least seven days
yielded similar results (Fig. 2). The number of pa-
tients who needed to be treated with levofloxacin
results
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to avoid a single episode of febrile neutropenia
was five.
A multivariate analysis that used multiple logistic
regression identified the use of antibacterial prophy-
laxis and a duration of profound neutropenia of at
least seven days as the only factors capable of influ-
encing the development of febrile episodes. Kap-
lan–Meier estimates of survival free of fever during
prophylaxis showed a clear advantage of levofloxa-
cin both overall (Fig. 3A) and among patients with
acute leukemia (Fig. 3B) and patients with solid tu-
mors or lymphoma (Fig. 3C).
 
microbial isolates and resistance 
to levofloxacin
 
Patients receiving prophylactic levofloxacin had a
significantly lower rate of microbiologically docu-
mented infections, gram-negative bacteremias, and
polymicrobial bacteremias than did those receiving
placebo. The number of bacteremias caused by a
 
Figure 1. Enrollment and Outcome.
760 Patients underwent
randomization
384 Assigned to levofloxacin 376 Assigned to placebo
9 Not eligible and did not
receive levofloxacin
13 Not eligible and did not
receive placebo
375 Treated
192 Had solid tumors
or lymphoma
183 Had leukemia
363 Treated
184 Had solid tumors 
or lymphoma
179 Had leukemia
339 Included in assessment 
of response
174 Had solid tumors 
or lymphoma
165 Had leukemia
336 Included in assessment 
of response
171 Had solid tumors 
or lymphoma
165 Had leukemia
4 Had protocol violation
1 Withdrew consent
6 Had nonbacterial infection
5 Did not have neutropenia
4 Had fever not due to infection
6 Received inappropriate
antibiotic therapy
8 Had interruption of treatment
for unknown reasons
1 Received no chemotherapy
1 Had increase in
aminotransferase levels 
to >3 times the upper limit
of normal
5 Had protocol violation
9 Withdrew consent
3 Had nonbacterial infection
2 Did not have neutropenia
3 Had fever not due to infection
2 Received inappropriate
antibiotic therapy
3 Had interruption of treatment
for unknown reasons
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Table 1. Characteristics of the 675 Patients Whose Response to Therapy Could Be Assessed.
Characteristic 
Patients with Solid Tumors 
or Lymphoma Patients with Leukemia
 
Levofloxacin
(N=174)
Placebo
(N=171)
Levofloxacin
(N=165)
Placebo
(N=165)
Age — yr
Mean 47 49 48 49
Range 19–72 18–70 18–75 18–75
Sex — no. (%)
 Male 102 (59) 93 (54) 88 (53) 87 (53)
 Female 72 (41) 78 (46) 77 (47) 78 (47)
Underlying cancer — no. (%)
 Acute leukemia — — 164 (99) 163 (99)
 Lymphoma and
 
 
 
Hodgkin’s disease 112 (64) 100 (58) — — 
 Solid tumor 24 (14) 22 (13) — -— 
 Other hematologic cancers 38 (22) 49 (29) 1 (1) 2 (1)
Chemotherapy — no. (%)
 First remission or induction — — 80 (48) 79 (48)
 
 
 
 Reinduction — — 37 (22) 32 (19)
 Augmentation — — 47 (28) 47 (28)
Stem-cell transplantation — no. (%) 158 (91) 149 (87) 12 (7) 9 (5)
Protective environment — no. (%)
 Single room 43 (25) 42 (25) 46 (28) 47 (28)
 Reverse isolation 28 (16) 27 (16) 19 (12)
 
 
 
18 (11)
 Laminar airflow room 25 (14) 26 (15) 11 (7) 13 (8)
 Other 19 (11) 21 (12) 9 (5) 7 (4)
 
 
 
Intravenous catheter in situ — no. (%) 156 (90) 156 (91) 107 (65) 116 (70)
Antifungal prophylaxis — no. (%) 148 (85) 155 (91) 154 (93) 152 (92)
Antiviral prophylaxis — no. (%) 107 (61) 110 (64) 29 (18) 38 (23)
Duration of prophylaxis — days
Mean 14 15 27 25
Range 4–36 5–61 9–65 6–70
Median 14 14 25 24
Duration of neutropenia (<1000 neutrophils/mm
 
3
 
) 
— days
Mean 9 9 20 18
Range 4–28 2–51 3–54 3–67
Median 8 8 19 15
Duration of severe
 
 
 
neutropenia (<100 neutrophils/mm
 
3
 
) 
— days
Mean 6 6 11 10
Range 0–20 0–49 0–47 0–38
Median 6 5 10 8
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single gram-positive organism was also reduced
among patients who received levofloxacin, but this
reduction only approached significance (Fig. 2).
The pathogens responsible for bacteremia and
those resistant to levofloxacin are listed in Table 2.
Data were available for 90 percent of infections
caused by a single agent in the levofloxacin group
(47 of 52) and 74 percent of such infections in the
placebo group (68 of 92).
Patients receiving prophylactic levofloxacin had
a striking decrease in gram-negative bacteremias,
especially those due to 
 
Escherichia coli
 
 (Table 2). Three
percent of patients given levofloxacin had levoflox-
acin-resistant gram-negative bacilli, as compared
with 1 percent of those receiving placebo (10 of 337
vs. 4 of 322; absolute difference in risk, 2 percent;
95 percent confidence interval, –0.4 to 3 percent;
P=0.10), even though among gram-negative iso-
lates from patients with bacteremia, a greater per-
centage of levofloxacin-resistant gram-negative
bacilli were documented in the former group than
in the latter (77 percent vs. 17 percent [10 of 13 vs.
4 of 24]).
There were fewer bacteremias due to 
 
Staphylo-
coccus aureus
 
 and streptococcus species in the levo-
floxacin group than in the placebo group (Table 2).
Among the gram-positive isolates tested, 91 per-
cent of those in the levofloxacin group and 64 per-
cent of those in the placebo group were resistant to
levofloxacin (31 of 34 and 28 of 44, respectively).
Methicillin-resistant, coagulase-negative staphylo-
cocci, all of which were also resistant to levofloxa-
cin, were the most frequent gram-positive isolates
in both groups.
 
clinically documented infections, fever 
of unknown origin, and antibiotic therapy
 
The numbers of clinically documented infections
and episodes of fever of unknown origin were sim-
ilar in the two groups (Fig. 2). The lung was the most
frequent site of origin of these infections (13 of 30
such infections among patients receiving levoflox-
acin and 16 of 33 among those receiving placebo),
also accounting for the most severe infections.
Empirical antibacterial therapy was administered
according to the protocol guidelines. An analysis
of the initial antibiotic regimens showed that the
most frequently used regimen consisted of a broad-
spectrum beta-lactam with an aminoglycoside (117
of 221 regimens in the levofloxacin group and 159
of 290 regimens in the placebo group). The second
choice was monotherapy with an antipseudomonas
beta-lactam (56 of 221 regimens and 72 of 290 reg-
imens, respectively). Combination therapy includ-
ing a glycopeptide and a beta-lactam with or with-
out an aminoglycoside was the least frequently used
regimen (48 of 221 regimens and 59 of 290 regi-
mens, respectively). There was no significant differ-
ence in the rates of use of preferred regimens be-
tween the two groups.
The total cost of antibiotics, on the basis of the
acquisition cost, was lower in the levofloxacin group
than in the placebo group. The mean cost per pa-
tient of antibiotics was ¤1,953 in the levofloxacin
group, as compared with ¤2,841 in the placebo
group (P<0.001).
 
subgroup analysis
 
As compared with the patients with solid tumors or
lymphoma who were undergoing hematopoietic
stem-cell transplantation, the patients with acute
leukemia had more sustained neutropenia (19 vs.
9 days with a neutrophil count of no more than
1000 per cubic millimeter) and more profound neu-
tropenia (11 vs. 6 days with a neutrophil count of
no more than 100 per cubic millimeter). Nonethe-
less, the efficacy of prophylaxis was similar in the
two subgroups. Moreover, a subanalysis confined
to the patients who had neutropenia for at least sev-
en days did not show any significant difference in
response rates between the two subgroups (Fig. 2).
 
compliance and adverse events
 
Compliance was good, and it was similar in the two
groups. There was a similar frequency of interrup-
tion of prophylaxis owing to adverse events in the
two groups: three patients with gastrointestinal dis-
turbances, three with rash, and one with seizure in
the levofloxacin group and two patients with rash
and one with rhabdomyolysis in the placebo group.
 
mortality
 
Data on mortality at the end of follow-up were avail-
able for 736 of 760 patients (Table 3). The overall
mortality rate was 4 percent (28 of 736 patients),
 
Figure 2 (facing page). Rates and Absolute Differences 
in the Risk of Primary and Secondary End Points.
 
The overall analysis of death among all treated patients 
excludes two patients in the levofloxacin group who 
were lost to follow-up. CI denotes confidence interval. 
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¡0.4 ¡0.3 ¡0.2 ¡0.1 0.0 0.1
Placebo
better
 
Levofloxacin
better
Gram-negative
infection
Gram-positive
Febrile episode
All treated patients
Death
All assessable patients
Febrile episode
Microbiologically documented
Polymicrobial
Bacteremia
Gram-positive
Gram-negative
Polymicrobial
Clinically documented infection
Fever of unknown origin
Assessable patients with
Febrile episode
Treated patients
Acute leukemia
neutropenia ≥7 days
Febrile episode
Assessable patients
infection
Febrile episode
Death
Microbiologically documented
Bacteremia
Assessable patients with
Treated patients 
Solid tumors or lymphoma
neutropenia for ≥7 days
Febrile episode
Febrile episode
Assessable patients
neutropenia for ≥7 days
infection
Febrile episode
Death
Microbiologically documented
Assessable patients with
Febrile episode
Bacteremia
Group and Event
21/339 (6)
42/339 (12)
243/375 (65)
10/373 (3)
221/339 (65)
74/339 (22)
11/339 (3)
62/339 (18)
37/339 (11)
15/339 (4)
10/339 (3)
30/339 (9)
117/339 (34)
200/300 (67)
123/183 (67)
113/165 (68)
9/182 (5)
39/165 (24)
34/165 (21)
120/192 (62)
110/159 (69)
108/174 (62)
1/191 (1)
35/174 (20)
90/141 (64)
28/174 (16)
Levofloxacin
no./total no. (%)
47/336 (14)
61/336 (18)
308/363 (85)
18/363 (5)
290/336 (86)
131/336 (39)
23/336 (7)
115/336 (34)
54/336 (16)
38/336 (11)
23/336 (7)
33/336 (10)
126/336 (37)
252/280 (90)
154/179 (86)
145/165 (88)
13/179 (7)
74/165 (45)
64/165 (39)
154/184 (84)
138/151 (91)
145/171 (85)
5/184 (3)
57/171 (33)
114/129 (88)
51/171 (30)
Placebo
¡0.08 (¡0.12 to ¡0.03)
¡0.06 (¡0.11 to ¡0.003)
¡0.20 (¡0.26 to ¡0.14)
¡0.02 (¡0.05 to 0.005)
¡0.21 (¡0.27 to ¡0.14)
¡0.17 (¡0.24 to ¡0.10)
¡0.04 (¡0.06 to ¡0.003)
¡0.16 (¡0.22 to ¡0.09)
¡0.05 (¡0.10 to 0.00)
¡0.07 (¡0.10 to ¡0.02)
¡0.04 (¡0.07 to ¡0.01)
¡0.01 (¡0.05 to 0.03)
¡0.03 (¡0.10 to 0.04)
¡0.23 (¡0.29 to ¡0.16)
¡0.19 (¡0.27 to ¡0.10)
¡0.20 (¡0.28 to ¡0.10)
¡0.02 (¡0.07 to 0.02)
¡0.21 (¡0.31 to ¡0.11)
¡0.18 (¡0.27 to ¡0.08)
¡0.22 (¡0.29 to ¡0.12)
¡0.22 (¡0.30 to ¡0.13)
¡0.23 (¡0.31 to ¡0.13)
¡0.02 (¡0.05 to 0.004)
¡0.13 (¡0.22 to ¡0.03)
¡0.24 (¡0.34 to ¡0.15)
¡0.14 (¡0.22 to ¡0.04)
Absolute Difference
in Risk (95% CI)
Absolute Difference
in Risk (95% CI)
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and death was more frequent among patients with
acute leukemia (accounting for 22 of 28 deaths)
than among patients with solid tumors or lym-
phoma. Three percent of patients died in the levo-
floxacin group, as compared with 5 percent in the
placebo group (10 of 373 vs. 18 of 363; absolute
difference in risk, ¡2 percent; 95 percent confidence
interval, ¡5 to 0.5 percent; P=0.15). Also, the infec-
tion-related mortality rate was similar in the two
groups, being 2 percent in the levofloxacin group
and 4 percent in the placebo group (9 of 373 and
14 of 363, respectively; absolute difference in risk,
¡2 percent; 95 percent confidence interval, ¡4 to
1 percent; P=0.36). Among the eight deaths occur-
ring among patients with single-agent bacteremias,
two were caused by gram-negative bacilli and both
were in the placebo group. The survival rate among
patients with single-agent bacteremias due to levo-
floxacin-resistant strains was similar in the two
groups: 95 percent in the levofloxacin group (39 of
41) and 97 percent in the placebo group (31 of 32).
The prophylactic use of fluoroquinolones in pa-
tients with cancer and neutropenia is controversial
and is not recommended.
 
15
 
 This double-blind, pla-
cebo-controlled trial was sufficiently large to pro-
vide clear evidence of the efficacy of bacterial pro-
phylaxis with a fluoroquinolone, as reflected by a
substantial reduction in the number of patients with
fever requiring empirical antibiotic therapy (num-
ber needed to treat to avoid one episode of fever,
five) as well as in the number of microbiologically
documented infections, including bacteremias due
to a single gram-negative isolate and polymicrobial
bacteremias. The reduction in microbiologically
documented infections was not accompanied by an
increase in the incidence of clinically documented
infections or fever of unknown origin, confirming
that the reduction was not simply due to a lower
discussion
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Figure 3. Kaplan–Meier Estimates of Survival Free 
from Fever among All Patients (Panel A), Patients 
with Acute Leukemia (Panel B), and Patients with Solid 
Tumors or Lymphoma (Panel C).
 
The log-rank test was used to determine the chi-square 
values.
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rate of documented infections as a result of pro-
phylaxis.
Our study provides important information on
the patients who may benefit most from prophy-
laxis. The study population was stratified into two
groups, defined a priori at different risk for infection
on the basis of the presumptive duration of neutro-
penia and the underlying disease. We found that the
efficacy of prophylaxis was similar in the two sub-
groups. A possible explanation for this finding is
that the majority of patients with solid tumors or
lymphoma, but not of those with leukemia, under-
went hematopoietic stem-cell transplantation, and
this aggressive approach may account for adjunctive
risk factors for bacterial infections other than neu-
tropenia.
Our study does not provide data on low-risk pa-
tients with cancer. We did not include such patients
in our study because the combination of a fluoro-
quinolone with amoxicillin and clavulanate repre-
sents the standard empirical treatment among fe-
brile “low-risk” patients with neutropenia.
 
16,17
 
 The
prophylactic use of fluoroquinolones would have
precluded their empirical use in these patients.
Our study provides evidence that prophylaxis is
economical because it reduces the number of pa-
tients who become febrile during periods of neutro-
penia and therefore reduces the need for antibiotic
therapy. However, our study has some limitations.
Two main criticisms have been made with respect
to the policy of the routine use of fluoroquinolones
as prophylaxis. First, their extensive use has been
blamed on the increase in resistance to these agents,
an effect that can limit their clinical efficacy. Sec-
ond, no study has yet demonstrated a survival ad-
vantage from prophylaxis.
Although our study was not designed to monitor
the emergence of resistance to fluoroquinolones,
we noted a greater number of levofloxacin-resistant
gram-negative strains among patients receiving le-
vofloxacin than among those receiving placebo.
However, the prevalence of gram-negative fluoro-
quinolone-resistant bacteremia did not differ sig-
nificantly between the two groups, and the pres-
ence of fluoroquinolone resistance did not seem to
affect clinical outcomes, such as infection-related
morbidity or mortality. Furthermore, there is some
evidence that fluoroquinolone resistance is a mul-
ticlonal
 
18
 
 and reversible
 
19,20
 
 phenomenon and is
not a reason to avoid the prophylactic use of these
compounds. On the other hand, the selective pres-
sure exerted by the use of fluoroquinolone prophy-
laxis may be counterbalanced largely by the de-
creased use of empirical antibacterial therapy, thus
limiting the risk of emergence of resistance to the
drugs used as empirical therapy. Careful monitor-
ing of this phenomenon is mandatory.
Although the absolute number of deaths was
lower in the levofloxacin group than in the placebo
 
Table 2. Characteristics of Bacterial Isolates and Number with Resistance 
to Levofloxacin.
Characteristic
Levofloxacin 
(N=339)
Placebo 
(N=336)
Microbiologically documented infection
 
74 131
No. with bacteremia 62 115
Single gram-positive isolate 37 54
 
S. aureus
 
0 10
Coagulase-negative staphylococcus 31 32
Streptococcus species 5 9
Other gram-positive organisms 1 3
 
 
 
Single gram-negative isolate 15 38
 
 
 
Pseudomonas species 6 8
 
E. coli
 
7 22
Other gram-negative organisms 2 8
Polymicrobial isolate 10 23
Gram-positive organisms only 5 5
Gram-positive and gram-negative organisms 5 18
No. without bacteremia 12 16
Single gram-positive isolate 5 7
Single gram-negative isolate 6 9
Polymicrobial isolate 1 0
 
Levofloxacin resistance in single-agent bacteremias 
— no. resistant/total no. available 
for analysis
 
41/47 32/68
 
 
 
Gram-positive isolate 31/34 28/44
 
S. aureus
 
0 1/7
Coagulase-negative staphylococcus 27/30 26/31
Streptococcus species 4/4 1/3
Other gram-positive organisms 0 0/3
Gram-negative isolate 10/13 4/24
Pseudomonas species 4/6 1/4
 
E. coli
 
5/5 2/16
Other gram-negative organisms 1/2 1/4
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group, we were not able to document a significant
effect of levofloxacin in the reduction of mortality.
Worldwide, the reported mortality rate due to bac-
terial infection in patients with cancer and neutro-
penia is approximately 5 percent
 
21,22
 
; thus, the
demonstration of a significant reduction in mortal-
ity owing to the use of bacterial prophylaxis would
have required a trial with a much larger sample size
than ours. Furthermore, the mortality rate among
patients with neutropenia is influenced by factors
unrelated to prophylaxis, such as the response to
empirical antibiotic therapy, the severity of under-
lying disease, and the presence of comorbidity.
Moreover, a recent observational trial performed at
a single center in a small number of patients with
hematologic cancers and neutropenia even sug-
gests that patients receiving fluoroquinolone pro-
phylaxis, despite high rates of fluoroquinolone re-
sistance, had a survival advantage over patients who
did not receive prophylaxis.
 
20
 
In conclusion, our study provides evidence that
prophylaxis with levofloxacin in high-risk patients
with neutropenia is effective, well tolerated, and
cost-effective but has no effect on the risk of death.
The observed reversibility of fluoroquinolone re-
sistance and the absence of a negative effect on clin-
ical outcomes are sufficient reasons to support the
use of fluoroquinolone prophylaxis in patients with
neutropenia. The decreased rate of complications
related to infection associated with the use of pro-
phylaxis can counterbalance the potential threats
of emerging resistance to levofloxacin. This con-
clusion contrasts with the lack of consensus in
some guidelines on the prophylactic use of fluoro-
quinolones in patients with neutropenia.
 
15
 
 Our re-
sults indicate that there is a need to reassess the
role of fluoroquinolones for this indication.
 
Supported in part by GlaxoSmithKline, Verona, Italy, and Aventis
Pharma, Italy.
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The GIMEMA Infection Program includes the following: 
 
Investigators and Centers 
 
— S. Ballanti (Policlinico Monteluce, Università di Perugia,
Perugia), G. Gentile (Università La Sapienza, Roma), S. Cinieri (Istituto Europeo di Oncologia, Milano), A. Levis (Ospedale San Antonio e
Biagio, Alessandria), G. Fioritoni (Ospedale Civile Santo Spirito, Pescara), T. Barbui (Ospedali Riuniti di Bergamo, Bergamo), E. Morra (Os-
pedale Niguarda, Milano), E. Brusa (Ospedale San Luigi, Orbassano-Torino), A. Zaccaria (Ospedale Santa Maria delle Croci, Ravenna), A.
Peta (Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro), V. Liso (Università di Bari, Bari), L. Cudillo (Ospedale Sant’ Eugenio, Roma), S.
Mirto (Azienda Ospedaliera Cervello, Palermo), C. Annaloro (Istituto di Ricovero e Cura a Carattere Scientifico [IRCCS], Ospedale Mag-
giore, Università di Milano, Milano), M. Tozzi (Università di Siena, Policlinico Le Scotte, Siena), M.E. Mitra (Policlinico Universitario, Pa-
lermo), A. De Blasio (Ospedale Santa Maria Goretti, Latina), F. Rossini (Università di Milano, Monza), G. Milone (Ospedale Ferrarotto, Cata-
nia), A. Cortellezzi (Università di Milano, Milano), G. Landonio (Ospedale Niguarda Ca’ Granda, Milano), M. Offidani (Ospedali Riuniti-
Università Politecnica delle Marche, Ancona), P. Servida (Divisione di Ematologia, Ospedale S. Raffaele, Milano), R. Invernizzi (Università
di Pavia, IRCCS, Policlinico San Matteo, Pavia), L. Castagna (Istituto Humanitas di Rozzano, Milano), N. Cascavilla (Ospedale Casa Sollievo
delle Sofferenze, IRCCS, San Giovanni Rotondo), M.A. Capucci (Ospedale Civile, Brescia), G. Trapè (Università Cattolica, Roma), D. Deru-
das (Università di Sassari, Sassari), M. Picardi (Università di Napoli, Napoli), D. Mattei (Azienda Ospedaliera Santa Croce Carle, Cuneo), R.
Sancetta (Ospedale Umberto I  Mestre, Venezia), A. D’Emilio (Ospedale San Bortolo, Vicenza), and C. Romani (Ospedale Oncologico Bus-
inco, Cagliari); 
 
Data-Review Committee —
 
 C. Cenci, C. Santeusanio, F. Mearelli, and I. Nicoletti (Università di Perugia, Policlinico Monteluce,
Perugia).
 
* Two patients were lost to follow-up.
 
 
Table 3. Mortality Rates in the Treated Population.
Variable
Levofloxacin
(N=373)*
Placebo
(N=363) P Value
 
no. of patients
 
Death
 
10 18 0.15
 
Death due to infection
 
9 14 0.36
Microbiologically documented 
infection
4 7 0.25
Microbiologically documented 
infection with bacteremia
3 5 0.34
Single gram-positive isolate 2 2
Single gram-negative isolate 0 2
Polymicrobial (gram-positive and 
gram-negative) 
isolate
1 1
Microbiologically documented 
infection without bacteremia
1 2 0.48
Single gram-positive isolate 0 1
Single gram-negative isolate 1 1
Clinically documented infection 2 4 0.33
Lung 1 2
Other site 1 2
Fever of unexplained origin 3 3 0.64
 
Death from noninfectious causes
 
1 4 0.17
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